我赞成
发表于 2025-3-21 19:36:27
书目名称Heart-Brain Interactions影响因子(影响力)<br> http://impactfactor.cn/if/?ISSN=BK0424968<br><br> <br><br>书目名称Heart-Brain Interactions影响因子(影响力)学科排名<br> http://impactfactor.cn/ifr/?ISSN=BK0424968<br><br> <br><br>书目名称Heart-Brain Interactions网络公开度<br> http://impactfactor.cn/at/?ISSN=BK0424968<br><br> <br><br>书目名称Heart-Brain Interactions网络公开度学科排名<br> http://impactfactor.cn/atr/?ISSN=BK0424968<br><br> <br><br>书目名称Heart-Brain Interactions被引频次<br> http://impactfactor.cn/tc/?ISSN=BK0424968<br><br> <br><br>书目名称Heart-Brain Interactions被引频次学科排名<br> http://impactfactor.cn/tcr/?ISSN=BK0424968<br><br> <br><br>书目名称Heart-Brain Interactions年度引用<br> http://impactfactor.cn/ii/?ISSN=BK0424968<br><br> <br><br>书目名称Heart-Brain Interactions年度引用学科排名<br> http://impactfactor.cn/iir/?ISSN=BK0424968<br><br> <br><br>书目名称Heart-Brain Interactions读者反馈<br> http://impactfactor.cn/5y/?ISSN=BK0424968<br><br> <br><br>书目名称Heart-Brain Interactions读者反馈学科排名<br> http://impactfactor.cn/5yr/?ISSN=BK0424968<br><br> <br><br>
CRUMB
发表于 2025-3-21 20:32:31
http://reply.papertrans.cn/43/4250/424968/424968_2.png
宽敞
发表于 2025-3-22 00:36:31
http://reply.papertrans.cn/43/4250/424968/424968_3.png
重画只能放弃
发表于 2025-3-22 07:45:00
D. G. Shermans has uncovered the hidden risks behind alternative investments through extensive research in the US, UK, Germany France, Italy Scandinavia and Switzerland. He also provides solutions to the problems identified. This book is particularly important in light of recent scandals such as Enron and WorldCom.
INCUR
发表于 2025-3-22 09:38:58
http://reply.papertrans.cn/43/4250/424968/424968_5.png
Obituary
发表于 2025-3-22 14:01:58
http://reply.papertrans.cn/43/4250/424968/424968_6.png
coltish
发表于 2025-3-22 18:33:58
http://reply.papertrans.cn/43/4250/424968/424968_7.png
custody
发表于 2025-3-22 22:21:12
http://reply.papertrans.cn/43/4250/424968/424968_8.png
Carminative
发表于 2025-3-23 03:09:47
http://reply.papertrans.cn/43/4250/424968/424968_9.png
发酵剂
发表于 2025-3-23 05:34:26
Thromboembolism in Nonrheumatic Atrial Fibrillation: What Have We Learned?In the mid-1980s, several groups of investigators initiated clinical trials to assess the value of antithrombotic medications for primary prevention of thromboembolism in patients with nonrheumatic atrial fibrillation (AF) (Table 1) . The results of four of these trials are now available.